Clinical and Experimental Ophthalmology · 2000 · 18 citations · 21 references
MedicineOphthalmologyPharmacotherapyNeuro-ophthalmologyOcular DiseaseOcular PharmacologyAnterior UveitisImmunopathology Of The EyeMultiple SclerosisMultiple Sclerosis PharmacotherapyOcular InflammationUveal DiseaseChronic UveitisHigh-dose MethylprednisoloneImmunosuppressive Therapy For UveitisMethylprednisolone UseMultiple Sclerosis TherapySteroid Adverse EffectsSystemic Immunosuppressive TherapyUveitis Pharmacotherapy
PURPOSE: To demonstrate the safety and effectiveness of intravenous methylprednisolone (IVMP) in the treatment of uveitis in association with multiple sclerosis (MS). METHODS: Uveitis is an unusual manifestation of MS that may be severe, chronic and require systemic immunosuppression therapy. High-dose IVMP has previously been shown to be effective in the treatment of inflammatory eye disease and MS. Eight episodes of uveitis in five patients with MS were treated over a 10-year period in an open, uncontrolled trial. Two patients had chronic anterior uveitis, one patient had bilateral panuveitis and two patients had intermediate uveitis. RESULTS: All patients responded to IVMP with evidence of a decrease in intraocular inflammatory activity and improved visual acuity (VA) within 2 weeks of commencing treatment. There were no severe ocular or systemic steroid side effects. CONCLUSIONS: Intravenous methylprednisolone is an effective, well-tolerated form of therapy for uveitis in patients with MS.
21
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Charles M. Poser, Donald W. Paty, Labe C. Scheinberg et al. · Annals of Neurology · 1983 · 7.4K citations
Intensive Immunosuppression in Progressive Multiple Sclerosis
Stephen L. Hauser, David M. Dawson, James R. Lehrich et al. · New England Journal of Medicine · 1983 · 826 citations
Pharmacy, Neurology, Pharmacotherapy +14
Aniki Rothová, H. J. Buitenhuis, Christina Meenken et al. · British Journal of Ophthalmology · 1992 · 324 citations · Full text